235 related articles for article (PubMed ID: 34581275)
1. Does perioperative biological therapy increase 30-day post-operative complication rates in inflammatory bowel disease patients undergoing intra-abdominal surgery? A systematic review.
Byrne LW; McKay D
Surgeon; 2021 Oct; 19(5):e153-e167. PubMed ID: 34581275
[TBL] [Abstract][Full Text] [Related]
2. Visceral adiposity and inflammatory bowel disease.
Rowan CR; McManus J; Boland K; O'Toole A
Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
[TBL] [Abstract][Full Text] [Related]
3. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
4. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
5. Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Abdominal Operations for Inflammatory Bowel Disease.
Lightner AL; Raffals LE; Mathis KL; Cima RR; Tse CS; Pemberton JH; Dozois EJ; Loftus EV
J Crohns Colitis; 2017 Feb; 11(2):185-190. PubMed ID: 27543504
[TBL] [Abstract][Full Text] [Related]
6. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
Gisbert JP; Chaparro M
J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
[TBL] [Abstract][Full Text] [Related]
7. Case-matched Comparison of Postoperative Outcomes Following Surgery for Inflammatory Bowel Disease After Exposure to Vedolizumab vs Other Biologics.
Novello M; Stocchi L; Steele SR; Holubar SD; Duraes LC; Kessler H; Shawki S; Hull LT
J Crohns Colitis; 2020 Feb; 14(2):185-191. PubMed ID: 31328222
[TBL] [Abstract][Full Text] [Related]
8. Biologics in inflammatory bowel disease: what are the data?
Côté-Daigneault J; Bouin M; Lahaie R; Colombel JF; Poitras P
United European Gastroenterol J; 2015 Oct; 3(5):419-28. PubMed ID: 26535119
[TBL] [Abstract][Full Text] [Related]
9. Risk and management of post-operative infectious complications in inflammatory bowel disease: A systematic review.
Mowlah RK; Soldera J
World J Gastrointest Surg; 2023 Nov; 15(11):2579-2595. PubMed ID: 38111772
[TBL] [Abstract][Full Text] [Related]
10. The Effect of Biologics on Postoperative Complications in Children With Inflammatory Bowel Disease and Bowel Resection.
Mitsuya JB; Gonzalez R; Thomas R; El-Baba M
J Pediatr Gastroenterol Nutr; 2019 Mar; 68(3):334-338. PubMed ID: 30247424
[TBL] [Abstract][Full Text] [Related]
11. Comparing persistence of new biologics to conventional anti-TNF alphas in adult patients with inflammatory bowel disease: a systematic review and meta-analysis protocol.
Yiu TH; Ko Y; Pudipeddi A; Natale P; Leong RW
BMJ Open; 2023 Oct; 13(10):e073071. PubMed ID: 37788929
[TBL] [Abstract][Full Text] [Related]
12. No effect of anti-TNF-α agents on the surgical stress response in patients with inflammatory bowel disease undergoing bowel resections: a prospective multi-center pilot study.
El-Hussuna A; Qvist N; Zangenberg MS; Langkilde A; Siersma V; Hjort S; Gögenur I
BMC Surg; 2018 Nov; 18(1):91. PubMed ID: 30390672
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis: peri-operative anti-TNFα treatment and post-operative complications in patients with inflammatory bowel disease.
Narula N; Charleton D; Marshall JK
Aliment Pharmacol Ther; 2013 Jun; 37(11):1057-64. PubMed ID: 23581515
[TBL] [Abstract][Full Text] [Related]
14. Risk of post-operative complications associated with anti-TNF therapy in inflammatory bowel disease.
Ali T; Yun L; Rubin DT
World J Gastroenterol; 2012 Jan; 18(3):197-204. PubMed ID: 22294822
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of blood concentration of biologics on endoscopic inactivity in inflammatory bowel disease: A systematic review.
Cao WT; Huang R; Jiang KF; Qiao XH; Wang JJ; Fan YH; Xu Y
World J Gastroenterol; 2021 Mar; 27(9):886-907. PubMed ID: 33727776
[TBL] [Abstract][Full Text] [Related]
16. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development.
Matro R; Martin CF; Wolf D; Shah SA; Mahadevan U
Gastroenterology; 2018 Sep; 155(3):696-704. PubMed ID: 29857090
[TBL] [Abstract][Full Text] [Related]
17. Dose Escalation Patterns of Advanced Therapies in Crohn's Disease and Ulcerative Colitis: A Systematic Literature Review.
Panaccione R; Lee WJ; Clark R; Kligys K; Campden RI; Grieve S; Raine T
Adv Ther; 2023 May; 40(5):2051-2081. PubMed ID: 36930430
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
19. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.
Lamb CA; Kennedy NA; Raine T; Hendy PA; Smith PJ; Limdi JK; Hayee B; Lomer MCE; Parkes GC; Selinger C; Barrett KJ; Davies RJ; Bennett C; Gittens S; Dunlop MG; Faiz O; Fraser A; Garrick V; Johnston PD; Parkes M; Sanderson J; Terry H; ; Gaya DR; Iqbal TH; Taylor SA; Smith M; Brookes M; Hansen R; Hawthorne AB
Gut; 2019 Dec; 68(Suppl 3):s1-s106. PubMed ID: 31562236
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
